Phase 1/2Completed
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte in Patients With Aging Frailty
- Sponsor
- Cellcolabs Clinical SPV Limited (Industry)
- Enrolment
- 12 enrolled
- Conditions
- Aging Frailty
- Interventions
- StromaForte
- Ages
- adults, older adults
- Registry
- NCT06063590
From the registry
This phase I/IIa study in frail patients is designed to assess the safety of intravenous human allogenic bone marrow-derived mesenchymal stromal cell product StromaForte by reporting the number of adverse events assessed by Common Terminology Criteria. 12 male and female patients aged 60 to 85 years will be enrolled.
Primary outcomes
- Safety